May 2Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Apr 25Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Mar 30ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Mar 9Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics
Jan 31Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023
Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial